Morgan Stanley Raises CAH Target to $286 as Second Earnings Date Looms

Cardinal Health reports again on November 5, just six days after its October 30 release, and the most consequential data point heading into that print is Morgan Stanley's decision last Thursday to lift its target from $265 to $286, reaffirming Overweight at a stock price of $250.

Analyst momentum has been uniformly positive for weeks. UBS raised its target to $295 on October 16. Mizuho went to $280 on October 20. Morgan Stanley's Thursday move, from $265 to $286, is the latest in a string of upward revisions that have kept consensus targets above the current price despite a 12% gain in the past month. The mean target is $273, implying around 9% upside from $250.48, but several individual targets now sit comfortably above that. JPMorgan remains the notable exception, holding at Neutral with a $260 target, the only major firm not positioned for outperformance.

The debate behind those ratings comes down to margin durability. The bull case is structural: Cardinal, Cencora, and McKesson collectively control more than 90% of US pharmaceutical distribution, and the company is tilting its mix toward higher-margin services in specialty, biosimilars, and nuclear medicine, with roughly $3 billion in MSO revenue and growing theranostics exposure. Bears focus on the fragility of that structure, pointing out that the core distribution business runs on low-single-digit gross margins, CVS accounts for around 30% of fiscal 2025 sales, and any adverse movement on drug pricing legislation or biosimilar economics hits a business with very little cushion. Forward earnings growth ranks in the 86th percentile of the ORTEX universe, but EPS surprise history ranks in just the 37th, a combination that suggests the market is pricing in delivery that the company has not consistently provided.

Short positioning has climbed 13% over the past week to 3.3% of free float, with 7.9 million shares short, continuing a trend that was flagged in an ORTEX convergence report published on October 27. That accumulation pace is notable against a stock that has already moved sharply higher, but the borrow market offers no sign of stress. Availability is at 7,663%, extremely loose, and the cost to borrow is 0.42%, barely above flat. Short sellers are adding exposure, not fighting a squeeze. The put/call ratio at 0.70 is just half a standard deviation above its 20-day average, a modest tilt rather than a defensive posture.

Past earnings reactions give context for the stakes. The three most recent prints each produced negative one-day moves: down 3.8%, down 1.5%, and down 1.3%, with five-day returns similarly negative in each case. The November 5 print will test whether the string of analyst target increases reflects conviction in a business that is genuinely re-rating, or whether the stock's recent run has simply pulled targets up behind it.